Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Segment Information - Summary of Segment Information (Detail)

v3.8.0.1
Segment Information - Summary of Segment Information (Detail) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
NET REVENUE                      
Total Revenue $ 67,792 $ 63,052 $ 66,090 $ 61,676 $ 60,489 $ 60,761 $ 63,129 $ 59,704 $ 258,611 $ 244,083 $ 99,802
Cost of revenue:                      
Cost of revenue                 138,295 133,704 56,046
Gross margin:                      
Total Gross Margin $ 33,132 $ 28,810 $ 31,178 $ 27,196 $ 27,256 $ 27,345 $ 28,605 $ 27,173 120,316 110,379 43,756
Clinical Testing [Member]                      
NET REVENUE                      
Total Revenue                 231,748 222,015 98,595
Cost of revenue:                      
Cost of revenue                 121,785 120,437 55,802
Gross margin:                      
Total Gross Margin                 109,963 101,578 42,793
Pharma Services [Member]                      
NET REVENUE                      
Total Revenue                 26,863 22,068 1,207
Cost of revenue:                      
Cost of revenue                 16,510 13,267 244
Gross margin:                      
Total Gross Margin                 $ 10,353 $ 8,801 $ 963